Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 2,000
Avg Vol 29,278
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 48%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, develops allogeneic stem cell-based and enveloped virus platforms to potentiate and deliver oncolytic viruses in the United States. Its product pipeline comprises CLD-101, which is in Phase 1b/2 clinical trial for the treatment of high-grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck squamous cell carcino...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 794 9600
Fax: 858 794 9605
Address:
4475 Executive Drive, Suite 200, San Diego, United States
Latest News on CLDWW
No data available.